These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34123798)

  • 1. Association of
    Wang X; Wu B; Yan Z; Wang G; Chen S; Zeng J; Tao F; Xu B; Ke H; Li M
    Front Oncol; 2021; 11():650122. PubMed ID: 34123798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types.
    Shang X; Zhang W; Zhang X; Yu M; Liu J; Cheng Y; Cheng B
    Front Immunol; 2022; 13():991091. PubMed ID: 36248841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTPRD/PTPRT mutation correlates to treatment outcomes of immunotherapy and immune landscape in pan-cancers.
    Wang G; Ji X; Wang H; Tang X; Xing X; Ji J
    Chin J Cancer Res; 2023 Jun; 35(3):316-330. PubMed ID: 37440827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
    Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
    BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Hsu HC; Lapke N; Chen SJ; Lu YJ; Jhou RS; Yeh CY; Tsai WS; Hung HY; Hsieh JC; Yang TS; Thiam TK; You JF
    Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30200630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.
    Zhang W; Shi F; Kong Y; Li Y; Sheng C; Wang S; Wang Q
    Cancer Med; 2022 Feb; 11(3):676-691. PubMed ID: 34862763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer.
    Ren Z; Wang L; Leng C
    Aging (Albany NY); 2023 Aug; 15(16):8204-8219. PubMed ID: 37602864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
    Zhang L; Han X; Shi Y
    JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer.
    Zhu G; Ren D; Lei X; Shi R; Zhu S; Zhou N; Zu L; Mello RA; Chen J; Xu S
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33808631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive role of galectin-3 for immune checkpoint blockades (ICBs) in advanced or metastatic non-small cell lung cancer: a potential new marker for ICB resistance.
    Kim JS; Kim S; Koh J; Kim M; Keam B; Kim TM; Lindmark B; Kim DW
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2355-2365. PubMed ID: 35976444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of nomogram associated with durable clinical benefit gene for advanced non-small cell lung cancer with sensitivity to responsive to immunotherapy.
    Wang L; Chu X; Yu X; Su C
    Heliyon; 2024 Apr; 10(7):e27801. PubMed ID: 38560208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of
    Cui Y; Zhang P; Liang X; Xu J; Liu X; Wu Y; Zhang J; Wang W; Zhang F; Guo R
    Am J Cancer Res; 2022; 12(4):1766-1783. PubMed ID: 35530271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eight gene mutation-based polygenic hazard score as a potential predictor for immune checkpoint inhibitor therapy outcome in metastatic melanoma.
    Zhao L; Luo T; Jiang J; Wu J; Zhang X
    Front Mol Biosci; 2022; 9():1001792. PubMed ID: 36120536
    [No Abstract]   [Full Text] [Related]  

  • 16. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
    Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
    BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors.
    Wang Z; Duan J; Wang G; Zhao J; Xu J; Han J; Zhao Z; Zhao J; Zhu B; Zhuo M; Sun J; Bai H; Wan R; Wang X; Fei K; Wang S; Zhao X; Zhang Y; Huang M; Huang D; Qi C; Gao C; Bai Y; Dong H; Xiong L; Tian Y; Wang D; Xu C; Wang W; Li J; Hu X; Cai S; Wang J
    J Thorac Oncol; 2020 Apr; 15(4):556-567. PubMed ID: 31843683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies.
    Sen M; Kindsfather A; Danilova L; Zhang F; Colombo R; LaPorte MG; Kurland BF; Huryn DM; Wipf P; Herman JG
    Epigenetics; 2020; 15(6-7):604-617. PubMed ID: 31595832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis.
    Kaufman HL; Schwartz LH; William WN; Sznol M; Fahrbach K; Xu Y; Masson E; Vergara-Silva A
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2245-2261. PubMed ID: 30132118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.